Investigator Initiated Trial to Evaluate the Efficacy of FEXUCLUE®40mg(Fexuprazan hydrochloride) in Patients with Iatrogenic Gastric Ulcer After Endoscopic Submucosal Dissectio
- Conditions
- Neoplasms
- Registration Number
- KCT0008892
- Lead Sponsor
- Presbyterian Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 105
? Those who receive ESD due to gastric cancer or hypothyroidism confined to the mucous membrane
? A person who is sensitive to the components of a clinical trial drug
? In the case of drugs that may affect the effectiveness of gastric acid secretion inhibitors as follows, those who took them within two weeks before endoscopic mucosal surgery
- - PPI, H2 receptor antagonists, mucosal protective anti-ulcer drugs
? Patients who are required to take combination of clinical trial drug licenses during the clinical trial period as follows
- Combination inhibitors (atazanavir, nelpinavir, or lilphibirin-containing preparations, etc.)
- Drugs that increase the risk of bleeding (such as aspirin, anti-coagulants, etc.)
- - Steroid, NSAID
? I've had surgery that can affect gastric acid secretion Let's.
? Those who are unable to undergo upper gastrointestinal endoscopy (e.g., esophageal disease, gastrointestinal bleeding, etc
? Endoscopic submucosal resection is prohibited (platelet reduction, coagulation disorder, etc.)
? People with clinically significant liver and kidney disease
? A person with a history of malignant tumors within three years
(However, in the case of malignant tumors except for malignant tumors of the digestive system, those who have been cured and have passed more than 3 years without recurrence from the date of judgment can register.)
? Person with bipolar disorder, anxiety disorder, panic disorder, physical form disorder, personality disorder, or other clinically significant psychiatric disorder
? a person who is pregnant or lactating
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with endoscopic artificial ulcers turned into scars
- Secondary Outcome Measures
Name Time Method Rate of delayed bleeding